---
title: "Pemvidutide"
canonical_url: https://peptidelibrary.app/library/pemvidutide
description: "Investigational dual agonist at the GLP-1 and glucagon receptors from Altimmune, weighted toward glucagon activity relative to others in its class. It is in development for obesity and for metabolic dysfunction-associated steatohepatitis, where reducing hepatic fat is the therapeutic target. Not FDA-approved, and efficacy and safety remain under investigation."
updated: 2026-11-07
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# Pemvidutide

Pemvidutide (also called ALT-801 or GLP-1/glucagon dual agonist) is a glucagon agonist in the GLP-1 Agonist class. Pemvidutide is a dual agonist at the GLP-1 and glucagon receptors with a deliberately weighted ratio favouring glucagon activity relative to other agents in the class.

Investigational dual agonist at the GLP-1 and glucagon receptors from Altimmune, weighted toward glucagon activity relative to others in its class. It is in development for obesity and for metabolic dysfunction-associated steatohepatitis, where reducing hepatic fat is the therapeutic target. Not FDA-approved, and efficacy and safety remain under investigation.

Also known as: ALT-801, GLP-1/glucagon dual agonist.

Categories: Fat Loss, GLP-1/Metabolic.

## Classification

- Type: Investigational GLP-1/glucagon agonist
- Mechanism class: GLP-1 Agonist
- Development stage: In clinical development
- Regulatory class: Investigational, not FDA-approved

## Mechanism

Pemvidutide is a dual agonist at the GLP-1 and glucagon receptors with a deliberately weighted ratio favouring glucagon activity relative to other agents in the class. GLP-1 receptor activation reduces food intake through hypothalamic and brainstem circuits, while glucagon receptor activation increases hepatic energy expenditure and drives fatty-acid oxidation in the liver. That emphasis is the rationale for its investigation in metabolic dysfunction-associated steatohepatitis, where reducing hepatic lipid is the therapeutic target, as well as in obesity. It is investigational and not approved for any indication.

Targets: GLP-1 receptor, Glucagon receptor.

Origin: Synthetic peptide dual agonist.

## Properties

- Molecular formula: C182H275N39O54
- Molecular weight: ≈4094 g/mol
- CAS number: 2538014-94-5
- Half-life: ~110 hours (EuPort™ albumin-binding domain; weekly dosing)
- Studied routes: Subcutaneous

## Evidence

- Evidence level: Clinical Trial Evidence
- Highest documented: Controlled human trials
- Human trials: 4
- Controlled human trials: 4
- Preclinical sources: 0
- Latest source: 2025

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study. Lancet. 2025. 2025. Controlled human trial. Population: Adults with biopsy-confirmed MASH and fibrosis stage F2–F3 (n=212) [Source](https://pubmed.ncbi.nlm.nih.gov/41237796/)
2. Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study. J Hepatol. 2025. 2025. Controlled human trial. Population: Adults with BMI ≥28 and liver fat ≥10% (n=94) [Source](https://pubmed.ncbi.nlm.nih.gov/39002641/)
3. NCT05295875 — Efficacy and Safety of ALT-801 in the Treatment of Obesity. Controlled human trial. Population: Adults with obesity (n=391). Completed; no results posted on ClinicalTrials.gov [Source](https://clinicaltrials.gov/study/NCT05295875)
4. NCT07795164 — Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH. Controlled human trial. Population: Adults with MASH (n=1,800 planned). Recruiting; no results [Source](https://clinicaltrials.gov/study/NCT07795164)

### Registered trials

- [NCT05295875](https://clinicaltrials.gov/study/NCT05295875)
- [NCT07795164](https://clinicaltrials.gov/study/NCT07795164)

## Safety

Side effects: Nausea; Vomiting; Heart-rate increase possible.

Risks: Not approved; WADA S0.

Human safety basis: Clinical trial reports

Key limitations: Not approved by the FDA for any use..

## Regulatory status

Pemvidutide has been studied under an Investigational New Drug application. It is not approved for marketing.

- FDA status: Investigational New Drug (IND)
- WADA status: Banned in Sport
- Availability: Research-Only

## Frequently asked questions

### What is Pemvidutide?

Investigational dual agonist at the GLP-1 and glucagon receptors from Altimmune, weighted toward glucagon activity relative to others in its class. It is in development for obesity and for metabolic dysfunction-associated steatohepatitis, where reducing hepatic fat is the therapeutic target. Not FDA-approved, and efficacy and safety remain under investigation.

### How does Pemvidutide work?

Pemvidutide is a dual agonist at the GLP-1 and glucagon receptors with a deliberately weighted ratio favouring glucagon activity relative to other agents in the class. GLP-1 receptor activation reduces food intake through hypothalamic and brainstem circuits, while glucagon receptor activation increases hepatic energy expenditure and drives fatty-acid oxidation in the liver.

### Is Pemvidutide FDA approved?

No. Pemvidutide is investigational: it is in clinical development and has not been approved by the FDA for any indication. Investigational status means trials are ongoing or complete but regulatory review has not resulted in approval, and efficacy and safety are still being established.

### Is Pemvidutide banned in sport?

Pemvidutide is recorded here as prohibited in sport. Athletes subject to anti-doping rules should check the current WADA Prohibited List directly, since it is revised annually and classifications change.

### What peptides are similar to Pemvidutide?

Compounds most often compared with Pemvidutide include Retatrutide, Survodutide, Cotadutide and Mazdutide. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [Efficacy and safety of pemvidutide in metabolic dysfunction-associated steatohepatitis: a GRADE-assessed meta-analysis of randomized controlled trials — Naunyn Schmiedebergs Arch Pharmacol, 2026](https://pubmed.ncbi.nlm.nih.gov/41879841/)
- [Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study — J Hepatol, 2025](https://pubmed.ncbi.nlm.nih.gov/39002641/)
- [Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study — Lancet, 2025](https://pubmed.ncbi.nlm.nih.gov/41237796/)
- [The dual GLP-1-glucagon agonist pemvidutide in MASH: a phase 2b trial — Lancet, 2025](https://pubmed.ncbi.nlm.nih.gov/41352959/)

Note: Dose figures are left out of this Markdown version. See the cited sources.
